Skip to main content

Advertisement

Table 1 Baseline characteristics of participants at trial entry: ITT population

From: S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial

  Variable SCCR (n = 20) CCR (n = 20) P value
Age, yrs: mean (SD)   59.6 (19.3) 60.4 (20.1) 0.90
Race Asian (Chinese) 20 (100.0%) 20 (100.0%) 1.00
Sex
  Males 15 (75.0%) 14 (70.0%) 0.72
  Females 5 (25.0%) 6 (30.0%) 0.72
Performance status
  0 13 (65.0%) 12 (60.0%) 0.74
  1 7 (35.0%) 8 (40.0%) 0.74
Histology
  Adenocarcinoma 9 (45.0%) 10 (50.0%) 0.75
  Squamous cellcarcinoma 7 (35.0%) 5 (25.0%) 0.49
  Large cell carcinoma 4 (20.0%) 5 (25.0%) 0.71
Stage of disease
  IIIA 16 (80.0%) 14 (70.0%) 0.47
  IIIB 4 (20.0%) 6 (30.0%) 0.47
Primary site
  Upper lobe 13 (65.0%) 15 (75.0%) 0.49
  Middle/lower lobe 7 (35.0%) 5 (25.0%) 0.49
  1. Note: ITT, intent-to-treat; SCCR, S-1, cisplatin and concurrent thoracic radiation; CCR, cisplatin and concurrent thoracic radiation; yrs, years; SD, standard deviation.